Improving the outcome in malignant pleural mesothelioma: Nonaggressive or aggressive approach?

Current Opinion in Oncology

Volumn 21, Issue 2, 2009, Pages 124-130

  Stahel, Rolf A ^a   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemotherapy; Mesothelioma; Multimodality therapy; Radiotherapy; Surgery

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IMMUNOTOXIN; MESOTHELIN IMMUNOTOXIN; MITOMYCIN C; NAVELBINE; PEMETREXED; RALTITREXED; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VATALANIB; VINBLASTINE; VINFLUNINE; VORINOSTAT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEBRILE NEUTROPENIA; HUMAN; LUNG RESECTION; MESOTHELIOMA; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURISY; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

HUMANS; MESOTHELIOMA; NEOADJUVANT THERAPY; PLEURAL NEOPLASMS; PULMONARY SURGICAL PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 62349096255     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328324bc30     Document Type: Review

References (76)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-1603.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366:397-408.
3. Baas P. Optimising survival in malignant mesothelioma. Lung Cancer 2007; 57 (Suppl 2):S24-S29.
4. Fennell DA, Saudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5:136-147.
5. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 2008; 132:397-401.
6. Kushitani K, Takeshima Y, Amatya VJ, et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 2007; 57:190-199.
7. Galateau-Salle F, Vignaud JM, Burke L, et al. Well differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol 2004; 28:534-540.
8. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-672.
9. Pelucchi C, Malvezzi M, La Vecchia C, et al. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90:1022-1024.
10. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:587-593.
11. Marinaccio A, Binazzi A, Cauzillo G, et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43:2722-2728.
12. Carbone RG, Terracini B, Marinaccio A, et al. Asbestos, pleural mesothelioma, and mortality in Italy. J Occup Environ Hyg 2008; 5:D55-D56.
13. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17:25-30.
14. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491-496.
15. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60:259-263.
16. Andreopoulou E, Ross PJ, O'Brien ME, et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004; 15:1406-1412.
17. Muers MF, Stephens PJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371:1685-1694. Phase III trial with three arms collapsed into two arms comparing active supportive care without or with by today's standards suboptimal first line chemotherapy.
18. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage HIB or IV nonsmall-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23:142-153.
19. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin vs. cisplatin alone in patients with malignant pleural mesothelioma. In J Clin Oncol 2003; 21:2636-2644.
20. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (poststudy) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16:923-927.
21. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881-6889.
22. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443-1448.
23. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370-373.
24. Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008; 99:51-56. Carboplatin and pemetrexed is well tolerated and active in elderly patients.
25. Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756-763.
26. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008; 26:3567-3572.
27. Janne PA, Simon GR, Langer CJ, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008; 26:1465-1471. Pemetrexed and gemcitabine combination chemotherapy have moderate clinical activity, similar to pemetrexed single-agent therapy.
28. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007; 25:4751-4756.
29. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912-3917.
30. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in nonresectable malignant pleural mesothelioma. Br J Cancer 2008; 99:44-50. Cisplatin and vinorelbine combination chemotherapy has good clinical activity.
31. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006; 17:270-275.
32. Sorensen JB, Sundstrom S, Perell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007; 2:147-152.
33. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26:1698-1704. Phase III study of second line pemetrexed versus best supportive care demonstrates response and delayed disease progression with chemotherapy.
34. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2008 May 15. [Ebub ahead of print] Confirmation of activity of vinorelbine in second line chemotherapy.
35. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008; 112:1555-1561.
36. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005; 48:157-169.
37. Nakas A, Martin Dear AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33:83-88. VATS pleurectomy/decortication is a valuable option for selected patients.
38. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54-63; discussion 63-55.
39. Van TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:948-953.
40. Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007; 31:765-770. [discussion 770-761].
41. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135:620-626. [626 e621-623]. A large retrospective description of surgical outcomes.
42. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004; 22:3451-3457.
43. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18:1196-1202. First prospective multicenter study on neoadjuvant chemotherapy and extrapleural pneumonectomy. Median survival of 19.8 months by intend to treat analysis and 23 months median survival for patients having undergone extrapleural pneumonectomy.
44. Ribi K, Bernhard J, Schuller JC, et al. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer 2008; 61:398-404.
45. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996; 224:288-294.
46. Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008; 85:257-264. [discussion 264].
47. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84:1685-1692. [discussion 1692-1683].
48. Ceresoli GL, Gridelli C, Santoro A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007; 12:850-863.
49. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128:138-146.
50. Stewart DJ, Martin-Ucar AE, Edwards JG, et al. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005; 27:373-378.
51. Opitz I, Kestenholz P, Lardinois D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006; 29:579-584.
52. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108:754-758.
53. de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999; 43:511-516.
54. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004; 91:9-10.
55. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84:18-22. Lack of benefit of prophylactic port radiation.
56. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63:334-338.
57. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122:788-795.
58. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65:640-645.
59. Allen AM, Schofield D, Hacker F, et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 2007; 69:1587-1592.
60. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007; 69:350-357.
61. Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11:2300-2304.
62. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25:2406-2413.
63. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50:83-86.
64. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007; 59:149-150.
65. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 2006; 24-.384S-384S.
66. Janne PA, Wang XFF, Krug LM, et al. Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307. Ann Oncol 2006; 17:216-217.
67. Nowak AK, Millward MJ, Francis PJ, et al. Phase II study of sunitib as second-line therapy in malignant pleural mesothelioma (MPM) [abstract #8063]. J Clin Oncol 2008; 26S.
68. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) [abstract #7526]. J Clin Oncol 2007; 25(18S).
69. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008; 113:808-814.
70. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48:291-296.
71. Kindler HL, Burris HA, 3rd, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2008 Jul 11. [Epub ahead of print]
72. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2008; 61:549-558.
73. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylaniiide hydroxamic acid. Clin Lung Cancer 2006; 7:257-261.
74. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53.
75. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-5149.
76. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007; 7:20.